Atea Pharmaceuticals (AVIR) Liabilities and Shareholders Equity (2019 - 2026)

Atea Pharmaceuticals' Liabilities and Shareholders Equity history runs 8 years deep, the most recent figure standing at $267.1 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 39.3% year-over-year to $267.1 million; the TTM figure through Mar 2026 stood at $1.3 billion (down 30.91% YoY), while the FY2025 annual figure was $315.2 million, down 32.16% from the prior year.
• Liabilities and Shareholders Equity was $267.1 million for Q1 2026 at Atea Pharmaceuticals, down from $315.2 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $717.2 million in Q1 2022 to a low of $267.1 million in Q1 2026.
• Historically, Liabilities and Shareholders Equity has averaged $529.9 million across 5 years, with a median of $553.0 million in 2024.
• The sharpest annual moves came in 2023 and 2026: Liabilities and Shareholders Equity fell 9.84% in 2023, then plunged 39.3% in 2026.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $666.7 million in 2022, then dropped by 10.76% to $595.0 million in 2023, then dropped by 21.9% to $464.7 million in 2024, then plunged by 32.16% to $315.2 million in 2025, then declined by 15.27% to $267.1 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $267.1 million (Q1 2026), $315.2 million (Q4 2025), and $343.0 million (Q3 2025), per Business Quant data.